Dr. McKay Discusses the CheckMate-214 Trial in RCC

Name: Dr. McKay Discusses the CheckMate-214 Trial in RCC
Uploaded: 2017-09-26T01:06:00.000Z
Description: Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

September 25, 2017

Rana R. McKay, MD

Video

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma (RCC).

The phase III CheckMate-214 study evaluated the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with metastatic clear cell RCC.

This was the first time that an agent had beat sunitinib (Sutent) in the first-line space, says McKay, but there is still a lot to be learned with this combination regarding patient selection.